Assessment of two new therapies for peptic ulcer disease: omeprazole and the prostaglandin analogues.
D000527:Alprostadil / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000818:Animals; D000897:Anti-Ulcer Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004381:Duodenal Ulcer / Q000188:drug therapy*; D016620:Enprostil; D005750:Gastric Juice / Q000378:metabolism; D005755:Gastrins / Q000378:metabolism; D006801:Humans; D016595:Misoprostol; D009853:Omeprazole / Q000009:adverse effects / Q000627:therapeutic use*; D011459:Prostaglandins E, Synthetic / Q000009:adverse effects / Q000627:therapeutic use*; D013276:Stomach Ulcer / Q000188:drug therapy*
D000897:Anti-Ulcer Agents; D005755:Gastrins; D011459:Prostaglandins E, Synthetic; D016595:Misoprostol; D000527:Alprostadil; D016620:Enprostil; D009853:Omeprazole